Fepixnebart  (Synonyms: LY-3016859)

Fepixnebart (LY3016859) is a humanized monoclonal hIgG4 antibody, which binds and neutralizes only TGFα and epiregulin with high affinity. Fepixnebart can be used for the study of diabetic nephropathy and broad-spectrum chronic pain, including diabetic peripheral neuropathic pain (DPNP), signs and symptoms of osteoarthritis (OA), and chronic low back pain (CLBP)^[1][2].

TGFA

145.44 kDa

2489584-93-0

Liquid

Colorless to light yellow

[Fepixnebart]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG4 kappa

• 
  Flow cytometric analysis of 1.5X10⁶ Balb/3T3 cells with Fepixnebart (HY-P990071, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 (S228P) kappa, Isotype Control (HY-P99003, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

• [1]. Boyles JS, et al. Structural basis of selectivity and neutralizing activity of a TGFα/epiregulin specific antibody. Protein Sci. 2016 Nov;25(11):2028-2036.  [Content Brief]

  [2]. James DE, et al. Population Pharmacokinetics and Pharmacodynamics of Fepixnebart (LY3016859) and Epiregulin in Patients with Chronic Pain. Clin Pharmacokinet. 2025 May;64(5):757-767.  [Content Brief]